Study KAN-101-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of KAN-101 in patients with celiac disease on a gluten free diet (GFD).~An overview of the two parts and proposed dose groups is given below:~Part A (SAD): Patients will receive a single dose of KAN-101.~Part B (MAD): Patients will receive three doses of either KAN-101 or placebo.
A safety study of KAN-101 in patients with celiac disease. The study has two parts:~Part A - first in human study in which patients receive a single dose of KAN-101~Part B - patients will receive three doses of either KAN-101 or placebo